U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C25H30ClN5O3.C6H8O4
Molecular Weight 628.116
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BERADILOL MONOETHYL MALEATE

SMILES

CCOC(=O)\C=C/C(O)=O.CC1CC(=O)NN=C1C2=CC=C(NCC(C)(C)NCC(O)COC3=CC(Cl)=CC=C3C#N)C=C2

InChI

InChIKey=TZXOVBAUUXGKJG-QGAMPUOQSA-N
InChI=1S/C25H30ClN5O3.C6H8O4/c1-16-10-23(33)30-31-24(16)17-5-8-20(9-6-17)28-15-25(2,3)29-13-21(32)14-34-22-11-19(26)7-4-18(22)12-27;1-2-10-6(9)4-3-5(7)8/h4-9,11,16,21,28-29,32H,10,13-15H2,1-3H3,(H,30,33);3-4H,2H2,1H3,(H,7,8)/b;4-3-

HIDE SMILES / InChI

Molecular Formula C6H8O4
Molecular Weight 144.1253
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C25H30ClN5O3
Molecular Weight 483.99
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/9147023,9468640,7912931

TZC-5665 (Oberadilol) is a pyridazinone derivative with vasodilatory and beta-adrenergic blocking activities and type III phosphodiesterase inhibitory action

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
PubMed

PubMed

TitleDatePubMed
Studies on agents with vasodilator and beta-blocking activities. V. Synthesis and pharmacological activity of the optical isomers of TZC-5665.
1998-01
Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs.
1997-04
Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs.
1994-05
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Orally administered TZC-5665 reduced end-diastolic left ventricular volume and exhibited a tendency to increase ejection fraction.
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:36:15 GMT 2025
Edited
by admin
on Mon Mar 31 21:36:15 GMT 2025
Record UNII
9G211L8M9H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENZONITRILE, 4-CHLORO-2-(3-((1,1-DIMETHYL-2-((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)AMINO)ETHYL)AMINO)-2-HYDROXYPROPOXY)-, MONO(ETHYL (2Z)-2-BUTENEDIOATE) (SALT)
Preferred Name English
BERADILOL MONOETHYL MALEATE
JAN  
Common Name English
BERADILOL MONOETHYL MALEATE [JAN]
Common Name English
TZC-5665
Common Name English
OBERADILOL MONOETHYL MALEATE
Common Name English
Code System Code Type Description
PUBCHEM
6449836
Created by admin on Mon Mar 31 21:36:15 GMT 2025 , Edited by admin on Mon Mar 31 21:36:15 GMT 2025
PRIMARY
CAS
114856-47-2
Created by admin on Mon Mar 31 21:36:15 GMT 2025 , Edited by admin on Mon Mar 31 21:36:15 GMT 2025
PRIMARY
FDA UNII
9G211L8M9H
Created by admin on Mon Mar 31 21:36:15 GMT 2025 , Edited by admin on Mon Mar 31 21:36:15 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY